Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITUX-MMP trial in severe mucous membrane pemphigoid
2024-514885-38-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cicatricial pemphigoid (CP) comparing Rituximab arm with Cyclophosphamide arm (2 arms). Primary endpoint: Remission at Month 12. Planned start Oct 2024; status: authorised.
02
Drugs
rituximabcyclophosphamide
03
Conditions
cicatricial pemphigoid (CP)
Beyond the preview
Go deeper on 2024-514885-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514885-38-00.